Clinical Trials
91 trialsANIMATE
University College, London
Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours
Catalysis SL
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
SportTherapy
University of Milano Bicocca
Prolgo-HL
St. Petersburg State Pavlov Medical University
AVENuE
University College, London
PLIMATH
Peter MacCallum Cancer Centre, Australia
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Northwestern University
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
Northwestern University
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma
University of Guadalajara
NICE-40
St. Petersburg State Pavlov Medical University
Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma
Hospital Universitario Dr. Jose E. Gonzalez
Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma
National Research Center for Hematology, Russia
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
New York Medical College
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
Zhejiang University
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
GB226
Genor Biopharma Co., Ltd.
A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT
Sun Yat-sen University
H10
European Organisation for Research and Treatment of Cancer - EORTC
A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma
Hebei Senlang Biotechnology Inc., Ltd.
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
HD16
University of Cologne
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
Oncotartis, Inc.
The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.
Chinese PLA General Hospital
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Chinese PLA General Hospital
BASALT
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NK Cells in Cord Blood Transplantation
M.D. Anderson Cancer Center
Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma
Peking University
(Optimist)
King Abdullah International Medical Research Center
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen
Chinese PLA General Hospital
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital
ProT4
University College, London
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma
Sichuan University
BV-ALLO
University Hospital, Caen
BeEAC-1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
Immune Cell, Inc.
GLIDE
Ciusss de L'Est de l'Île de Montréal
Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation
Hospital Universitario Dr. Jose E. Gonzalez
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Auto-HBO
University of Kansas Medical Center
Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
Sheba Medical Center
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
Sheba Medical Center
Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Maria Sklodowska-Curie National Research Institute of Oncology